Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gout
Tuhina Neogi
New England Journal of Medicine (2011) Vol. 364, Iss. 5, pp. 443-452
Closed Access | Times Cited: 471

Showing 1-25 of 471 citing articles:

2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
Dinesh Khanna, John FitzGerald, Puja P. Khanna, et al.
Arthritis Care & Research (2012) Vol. 64, Iss. 10, pp. 1431-1446
Open Access | Times Cited: 1493
2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
Tuhina Neogi, Tim Jansen, Nicola Dalbeth, et al.
Annals of the Rheumatic Diseases (2015) Vol. 74, Iss. 10, pp. 1789-1798
Open Access | Times Cited: 748
2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Tuhina Neogi, Tim Jansen, Nicola Dalbeth, et al.
Arthritis & Rheumatology (2015) Vol. 67, Iss. 10, pp. 2557-2568
Open Access | Times Cited: 495
How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy
Georg Schett, Dirk Elewaut, Iain B. McInnes, et al.
Nature Medicine (2013) Vol. 19, Iss. 7, pp. 822-824
Closed Access | Times Cited: 381
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
Naomi Schlesinger, Rieke Alten, Thomas Bardin, et al.
Annals of the Rheumatic Diseases (2012) Vol. 71, Iss. 11, pp. 1839-1848
Closed Access | Times Cited: 319
Computational Phenotype Discovery Using Unsupervised Feature Learning over Noisy, Sparse, and Irregular Clinical Data
Thomas A. Lasko, Joshua C. Denny, Mia Levy
PLoS ONE (2013) Vol. 8, Iss. 6, pp. e66341-e66341
Open Access | Times Cited: 311
High-Risk Prescribing and Incidence of Frailty Among Older Community-Dwelling Men
Danijela Gnjidic, Sarah N. Hilmer, Fiona Blyth, et al.
Clinical Pharmacology & Therapeutics (2012) Vol. 91, Iss. 3, pp. 521-528
Open Access | Times Cited: 283
Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra
Tania O. Crişan, Maartje C. P. Cleophas, Marije Oosting, et al.
Annals of the Rheumatic Diseases (2015) Vol. 75, Iss. 4, pp. 755-762
Closed Access | Times Cited: 233
The genetics of hyperuricaemia and gout
Anthony M. Reginato, David B. Mount, Irene Yang, et al.
Nature Reviews Rheumatology (2012) Vol. 8, Iss. 10, pp. 610-621
Open Access | Times Cited: 227
Is it time to revise the normal range of serum uric acid levels?
Giovambattista Desideri, Giuseppe Castaldo, Alecio F. Lombardi, et al.
PubMed (2014) Vol. 18, Iss. 9, pp. 1295-306
Closed Access | Times Cited: 224
Necroinflammation in Kidney Disease
Shrikant R. Mulay, Andreas Linkermann, Hans‐Joachim Anders
Journal of the American Society of Nephrology (2015) Vol. 27, Iss. 1, pp. 27-39
Open Access | Times Cited: 209
Molecular Pathophysiology of Gout
Jyaysi Desai, Stefanie Steiger, Hans‐Joachim Anders
Trends in Molecular Medicine (2017) Vol. 23, Iss. 8, pp. 756-768
Closed Access | Times Cited: 199
Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study
Tai-Ming Ko, Chang‐Youh Tsai, Shih-Yang Chen, et al.
BMJ (2015), pp. h4848-h4848
Open Access | Times Cited: 185
Management of Gout and Hyperuricemia in CKD
Ana Beatriz Vargas‐Santos, Tuhina Neogi
American Journal of Kidney Diseases (2017) Vol. 70, Iss. 3, pp. 422-439
Open Access | Times Cited: 179
TET2-mutant clonal hematopoiesis and risk of gout
Mridul Agrawal, Abhishek Niroula, Pierre Cunin, et al.
Blood (2022) Vol. 140, Iss. 10, pp. 1094-1103
Open Access | Times Cited: 110
Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors
Robert Terkeltaub, Daniel E. Furst, Jennifer L. DiGiacinto, et al.
Arthritis & Rheumatism (2011) Vol. 63, Iss. 8, pp. 2226-2237
Closed Access | Times Cited: 219
Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review
Ching-Wei Tsai, Shih‐Yi Lin, Chin‐Chi Kuo, et al.
PLoS ONE (2017) Vol. 12, Iss. 1, pp. e0170393-e0170393
Open Access | Times Cited: 169
Uric acid as one of the important factors in multifactorial disorders – facts and controversies
Daria Pašalić, Natalija Marinković, Lana Feher-Turković
Biochemia Medica (2012), pp. 63-75
Open Access | Times Cited: 160
Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout
William J. Taylor, Jaap Fransen, Tim Jansen, et al.
Arthritis Care & Research (2015) Vol. 67, Iss. 9, pp. 1304-1315
Open Access | Times Cited: 132
Mechanistic Aspects of Inflammation and Clinical Management of Inflammation in Acute Gouty Arthritis
Bruce N. Cronstein, Prashanth Sunkureddi
JCR Journal of Clinical Rheumatology (2013) Vol. 19, Iss. 1, pp. 19-29
Open Access | Times Cited: 132
Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout
Andrea Klauser, Ethan J. Halpern, Sylvia Strobl, et al.
JAMA Cardiology (2019) Vol. 4, Iss. 10, pp. 1019-1019
Open Access | Times Cited: 122
Crystal Formation in Inflammation
Bernardo S. Franklin, Matthew Mangan, Eicke Latz
Annual Review of Immunology (2016) Vol. 34, Iss. 1, pp. 173-202
Closed Access | Times Cited: 118
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Jeffrey N. Miner, Philip K. Tan, David Hyndman, et al.
Arthritis Research & Therapy (2016) Vol. 18, Iss. 1
Open Access | Times Cited: 118
Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout: A Randomized Clinical Trial
Thomas H. Taylor, John N. Mecchella, Robin J. Larson, et al.
The American Journal of Medicine (2012) Vol. 125, Iss. 11, pp. 1126-1134.e7
Closed Access | Times Cited: 116
Alcohol Quantity and Type on Risk of Recurrent Gout Attacks: An Internet-based Case-crossover Study
Tuhina Neogi, Clara Chen, Jingbo Niu, et al.
The American Journal of Medicine (2014) Vol. 127, Iss. 4, pp. 311-318
Open Access | Times Cited: 115
Page 1 - Next Page

Scroll to top